Stock Movers: Palantir Slides, Novo Nordisk Boosts Bid, Spotify Beats User Expectations

Palantir Technologies Stock Performance

• 📉 Palantir Technologies (PLTR) shares experienced a significant drop, falling as much as 10% in a single day, marking its worst performance since May.
• 💡 This decline occurred despite the company reporting strong financial results, beating expectations for the 21st consecutive quarter.
• ⚠️ Concerns are mounting regarding the company's premium valuation, with its trailing price-to-sales ratio at 85, the highest in the S&P 500.
• 🐻 Noteworthy is the disclosure of bearish wagers on Palantir by Michael Burry's Scion Asset Management, adding to market skepticism.

Novo Nordisk and Metsera Acquisition Battle

• 🚀 Novo Nordisk (NVO) confirmed an updated bid to acquire Metsera (MTSR), intensifying the competition for the obesity startup.
• 📈 Metsera shares surged as much as 18% on the news, hitting a record high, underscoring the high interest in the fast-growing obesity drug market.
• ⚖️ The increased bids come ahead of a court battle, highlighting a significant M&A street fight.
• 💊 Hims and Hers is also reportedly in talks with Novo Nordisk regarding its upcoming obesity pill, further emphasizing the focus on this sector.

Spotify User Growth and Revenue

• 📊 Spotify Technology (SPOT) reported third-quarter results that surpassed analyst expectations for both active users and revenue.
• 👥 Monthly active users grew 11% year-over-year to 713 million, exceeding estimates.
• 💰 Revenue increased by 7% to €4.27 billion ($4.9 billion), also beating projections.
• ⚠️ Despite beating user and revenue expectations, ad-supported revenue saw a decline.
• 📉 Shares experienced a notable drop, falling as much as 6.4% from their May lows.